Supplementary materials: Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

These are peer-reviewed supplementary materials for the article 'Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema' published in the Journal of Comparative Effectiveness Research.

Supplementary data

• Supplementary Table 1: Inclusion and exclusion criteria for the 2018 SLR.
• Supplementary Table 2: Trial design of the studies in the evidence network.

Supplementary methods

• Statistical details on methodology

Aim: With no head-to-head studies comparing the effectiveness of lanadelumab and berotralstat for prevention of hereditary angioedema (HAE) attacks, this networkmeta-analysis (NMA) aimed to indirectly compare the effectiveness of these treatments. Materials & methods: The NMA, using the published data from Phase III trials, was performed using a frequentist weighted regression-based approach following Rucker et al. Efficacy outcomes of interest were HAE attack rate per 28 days and ≥90% reduction in monthly HAE attacks. Results & conclusion: In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.